Compound News and Research

RSS

Novel protein haditoxin in King Cobra's venom discovered

The King Cobra continues to weave its charm with researchers identifying a protein in its venom with the potential for new drug discovery and to advance understanding of disease mechanisms.

9 Mar 2010

MicroConstants acquires access to new nanosizing technology

MicroConstants, a GLP-compliant Contract Research Organization specializing in bioanalytical and pharmacokinetic analysis, has acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier.

9 Mar 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

8 Mar 2010

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences, LLC, announced today the finalization of the acquisition of the Discovery and Preclinical business of MDS Pharma Services with facilities and almost 600 associates in Bothell, Washington; Lyon, France; and Taipei, Taiwan.

8 Mar 2010

GeneGo's industry-FDA MetaTox partnership program: Tools and contents released

GeneGo announces the release of the first set of tools and content to come out of its industry-FDA MetaTox™ partnership program. The MetaTox partnership is developing a unique comprehensive systems toxicology suite designed for compound safety assessment in chemical and pharmaceutical R&D.

8 Mar 2010

Research group performs randomized study to evaluate efficacy of ICCBco in treatment of lung lesions

To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.

6 Mar 2010

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.

6 Mar 2010

Study: Bacteria, fungi and other microbes live in our gut are essential contributors to good health

The thousands of bacteria, fungi and other microbes that live in our gut are essential contributors to our good health. They break down toxins, manufacture some vitamins and essential amino acids, and form a barrier against invaders. A study published today in Nature shows that, at 3.3 million, microbial genes in our gut outnumber previous estimates for the whole of the human body.

4 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Anavex Life Sciences Corp. today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

4 Mar 2010

Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001

ExonHit Therapeutics today reported the signing by Allergan, Inc. and Bristol-Myers Squibb Company of a global exclusive license agreement for the development and commercialization of EHT/AGN 0001 (AGN-209323), ExonHit’s lead compound from the most advanced program of its collaboration with Allergan.

4 Mar 2010

Study suggests vitamin D supplements may decrease insulin resistance, fight depression

A daily dose of vitamin D may just be what Chicagoans need to get through the long winter, according to researchers at Loyola University Chicago Marcella Niehoff School of Nursing (MNSON). This nutrient lifts mood during cold weather months when days are short and more time is spent indoors.

4 Mar 2010

$Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer$

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.

3 Mar 2010

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Bristol-Myers Squibb Company and Allergan, Inc. today announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain.

3 Mar 2010

Drinking coffee may lower risk of hospitalization for heart rhythm disturbances

Coffee drinkers may be less likely to be hospitalized for heart rhythm disturbances, according to a new study by the Kaiser Permanente Division of Research in Oakland, Calif. The researchers, who note the findings may be surprising because patients frequently report palpitations after drinking coffee, are presenting the study at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in San Francisco on March 5, 2010.

3 Mar 2010

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009.

2 Mar 2010

MAP Pharmaceuticals announces net loss of $13.4M for fourth-quarter 2009

MAP Pharmaceuticals, Inc. today announced financial results for the fourth quarter and year ended December 31, 2009.

2 Mar 2010

Consumption of garlic reduces level of potential carcinogenic processes

Researchers have designed a urine test that can simultaneously measure the extent of a potential carcinogenic process and a marker of garlic consumption in humans.

2 Mar 2010

Agilent Technologies launches industry’s first transportable GC/MS system delivering laboratory-quality analysis

Agilent Technologies Inc. today introduced the 5975T Low Thermal Mass (LTM) Gas Chromatography/Mass Spectrometry Detector (GC/MSD), the industry’s first commercial transportable GC/MS system that delivers laboratory-quality analysis. Using proprietary LTM technology, Agilent has developed the 5975T LTM GC/MS to be smaller, more rugged and to consume less power than in-lab GC/MS instruments, yet capable of the same high-quality performance in the field.

2 Mar 2010

Compound News and Research

Novel protein haditoxin in King Cobra's venom discovered

MicroConstants acquires access to new nanosizing technology

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

GeneGo's industry-FDA MetaTox partnership program: Tools and contents released

Research group performs randomized study to evaluate efficacy of ICCBco in treatment of lung lesions

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Study: Bacteria, fungi and other microbes live in our gut are essential contributors to good health

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001

Study suggests vitamin D supplements may decrease insulin resistance, fight depression

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Drinking coffee may lower risk of hospitalization for heart rhythm disturbances

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

MAP Pharmaceuticals announces net loss of $13.4M for fourth-quarter 2009

Consumption of garlic reduces level of potential carcinogenic processes

Agilent Technologies launches industry’s first transportable GC/MS system delivering laboratory-quality analysis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News